Tag Archives: RedHill Biopharma

January, 2017

16 January
FDA Grants Redhill Biopharma’s Treatment for Nontuberculous Mycobacteria Infections QIDP Fast Track Designation

RHB-104 has been granted Qualified Infectious Disease Product (QIDP) designation by the U.S. FDA for the treatment of Nontuberculous Mycobacteria (NTM) Infection Under FDA’s Generating Antibiotic Incentives Now (GAIN) Act, QIDP designation allows for Fast-Track status and Priority Review, potentially leading to a shorter NDA review time by the FDA, …
Share

22 June
RedHill Biopharma’s Crohn’s Disease Drug Shows Potential Efficacy in Trial

TEL-AVIV, Israel, June 22, 2016 RedHill Biopharma Ltd. (NASDAQ: RDHL) (TASE: RDHL) (“RedHill” or the “Company”), a biopharmaceutical company primarily focused on development and commercialization of late clinical-stage, proprietary, orally-administered, small molecule drugs for inflammatory and gastrointestinal diseases and cancer, today announced the publication of an article demonstrating the potential …
Share